The Cochrane Library: Cochrane Database of Systematic Reviews

DOI: 10.1002/14651858

Reviews/Protocols listed by Cochrane Review Group


  1. Cochrane Acute Respiratory Infections Group
  2. Cochrane Airways Group
  3. Cochrane Anaesthesia Group
  4. Cochrane Back Group
  5. Cochrane Bone, Joint and Muscle Trauma Group
  6. Cochrane Breast Cancer Group
  7. Cochrane Childhood Cancer Group
  8. Cochrane Colorectal Cancer Group
  9. Cochrane Consumers and Communication Group
  10. Cochrane Cystic Fibrosis and Genetic Disorders Group
  11. Cochrane Dementia and Cognitive Improvement Group
  12. Cochrane Depression, Anxiety and Neurosis Group
  13. Cochrane Developmental, Psychosocial and Learning Problems Group
  14. Cochrane Drugs and Alcohol Group
  15. Cochrane Ear, Nose and Throat Disorders Group
  16. Cochrane Effective Practice and Organisation of Care Group
  17. Cochrane Epilepsy Group
  18. Cochrane Eyes and Vision Group
  19. Cochrane Fertility Regulation Group
  20. Cochrane Gynaecological Cancer Group
  21. Cochrane Haematological Malignancies Group
  22. Cochrane Heart Group
  23. Cochrane Hepato-Biliary Group
  24. Cochrane HIV/AIDS Group
  25. Cochrane Hypertension Group
  26. Cochrane Incontinence Group
  27. Cochrane Infectious Diseases Group
  28. Cochrane Inflammatory Bowel Disease and Functional Bowel Disorders Group
  29. Cochrane Injuries Group
  30. Cochrane Lung Cancer Group
  31. Cochrane Menstrual Disorders and Subfertility Group
  32. Cochrane Metabolic and Endocrine Disorders Group
  33. Cochrane Methodology Review Group
  34. Cochrane Movement Disorders Group
  35. Cochrane Multiple Sclerosis and Rare Diseases of the Central Nervous System Group
  36. Cochrane Musculoskeletal Group
  37. Cochrane Neonatal Group
  38. Cochrane Neuromuscular Disease Group
  39. Cochrane Occupational Safety and Health Group
  40. Cochrane Oral Health Group
  41. Cochrane Pain, Palliative and Supportive Care Group
  42. Cochrane Peripheral Vascular Diseases Group
  43. Cochrane Pregnancy and Childbirth Group
  44. Cochrane Prostatic Diseases and Urologic Cancers Group
  45. Cochrane Public Health Group
  46. Cochrane Renal Group
  47. Cochrane Schizophrenia Group
    1. About this group
    2. Reviews
      1. Acetylcholinesterase inhibitors for schizophreniaReview
      2. Acupuncture for schizophreniaReview
      3. Advance treatment directives for people with severe mental illnessReview
      4. Amisulpride for schizophreniaReview
      5. Amisulpride versus other atypical antipsychotics for schizophreniaReview
      6. Amphetamines for schizophreniaReview
      7. Anticholinergic medication for neuroleptic-induced tardive dyskinesiaReview
      8. Anticholinergic medication for non-clozapine neuroleptic-induced hypersalivation in people with schizophreniaReview
      9. Anticholinergics for neuroleptic-induced acute akathisiaReview
      10. Antidepressants for people with both schizophrenia and depressionReview
      11. Antidepressants for the negative symptoms of schizophreniaReview
      12. Antipsychotic drug treatment for elderly people with late-onset schizophreniaReview
      13. Antipsychotic drugs for non-affective psychosis during pregnancy and postpartumReview
      14. Antipsychotic medication for childhood-onset schizophreniaReview
      15. Antipsychotic medication for early episode schizophreniaReview
      16. Antipsychotic medication for elderly people with schizophreniaReview
      17. Antipsychotic medication versus placebo for people with both schizophrenia and learning disabilityReview
      18. Antipsychotic switching for people with schizophrenia who have neuroleptic-induced weight or metabolic problemsReview
      19. Aripiprazole for schizophreniaReview
      20. Aripiprazole versus other atypical antipsychotics for schizophreniaReview
      21. Aripiprazole versus placebo for schizophreniaReview
      22. Aripiprazole versus typical antipsychotic drugs for schizophreniaReview
      23. Art therapy for schizophrenia or schizophrenia-like illnessesReview
      24. 'As required' medication regimens for seriously mentally ill people in hospitalReview
      25. Assertive community treatment for people with severe mental disordersReviewWithdrawn
      26. Atypical antipsychotics for people with both schizophrenia and depressionReview
      27. Atypical antipsychotics for psychosis in adolescentsReview
      28. Ayurvedic medicine for schizophreniaReview
      29. Benperidol for schizophreniaReview
      30. Benzodiazepines for catatonia in people with schizophrenia and other serious mental illnessesReview
      31. Benzodiazepines for neuroleptic-induced acute akathisiaReview
      32. Benzodiazepines for neuroleptic-induced tardive dyskinesiaReview
      33. Benzodiazepines for psychosis-induced aggression or agitationReview
      34. Benzodiazepines for schizophreniaReview
      35. Beta-blocker supplementation of standard drug treatment for schizophreniaReview
      36. Bromperidol decanoate (depot) for schizophreniaReview
      37. Calcium channel blockers for neuroleptic-induced tardive dyskinesiaReview
      38. Cannabis and schizophreniaReview
      39. Carbamazepine for schizophreniaReview
      40. Case management for people with severe mental disordersReviewWithdrawn
      41. Central action beta-blockers versus placebo for neuroleptic-induced acute akathisiaReview
      42. Cessation of medication for people with schizophrenia already stable on chlorpromazineReview
      43. Chinese herbal medicine for schizophreniaReview
      44. Chlorpromazine dose for people with schizophreniaReview
      45. Chlorpromazine for psychosis induced aggression or agitationReview
      46. Chlorpromazine versus placebo for schizophreniaReview
      47. Cholinergic medication for neuroleptic-induced tardive dyskinesiaReview
      48. Clotiapine for acute psychotic illnessesReview
      49. Clozapine combined with different antipsychotic drugs for treatment resistant schizophreniaReview
      50. Clozapine versus other atypical antipsychotics for schizophreniaReview
      51. Clozapine versus typical neuroleptic medication for schizophreniaReview
      52. Cognitive behaviour therapy versus other psychosocial treatments for schizophreniaReview
      53. Cognitive behavioural therapy (brief versus standard duration) for schizophreniaReview
      54. Cognitive behavioural therapy versus other psychosocial treatments for schizophreniaReview
      55. Cognitive rehabilitation for people with schizophrenia and related conditionsReview
      56. Collaborative care approaches for people with severe mental illnessReview
      57. Community mental health teams (CMHTs) for people with severe mental illnesses and disordered personalityReview
      58. Compliance therapy for schizophreniaReview
      59. Compulsory community and involuntary outpatient treatment for people with severe mental disordersReview
      60. Containment strategies for people with serious mental illnessReview
      61. Crisis intervention for people with severe mental illnessesReview
      62. Dance therapy for schizophreniaReview
      63. Day centres for severe mental illnessReview
      64. Day hospital versus admission for acute psychiatric disordersReview
      65. Day hospital versus outpatient care for people with schizophreniaReview
      66. Depot fluphenazine decanoate and enanthate for schizophreniaReview
      67. Depot fluspirilene for schizophreniaReview
      68. Depot haloperidol decanoate for schizophreniaReview
      69. Depot perphenazine decanoate and enanthate for schizophreniaReview
      70. Depot pipotiazine palmitate and undecylenate for schizophreniaReview
      71. Depot risperidone for schizophreniaReview
      72. Distraction techniques for schizophreniaReview
      73. Drama therapy for schizophrenia or schizophrenia-like illnessesReview
      74. Droperidol for acute psychosisReview
      75. Early intervention for psychosisReview
      76. Educational games for mental health professionalsReview
      77. Electroconvulsive therapy for schizophreniaReview
      78. Estrogen for schizophreniaReview
      79. Exercise therapy for schizophreniaReview
      80. Family intervention (brief) for schizophreniaReview
      81. Family intervention for schizophreniaReview
      82. Flupenthixol decanoate (depot) for schizophrenia or other similar psychotic disordersReview
      83. Flupenthixol versus low-potency first-generation antipsychotic drugs for schizophreniaReviewNew
      84. Flupenthixol versus placebo for schizophreniaReview
      85. Fluphenazine (oral) versus placebo for schizophreniaReview
      86. Fluphenazine versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      87. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesiaReview
      88. General physical health advice for people with serious mental illnessReview
      89. Glutamatergic drugs for schizophreniaReview
      90. Haloperidol dose for the acute phase of schizophreniaReview
      91. Haloperidol for psychosis-induced aggression or agitation (rapid tranquillisation)Review
      92. Haloperidol plus promethazine for psychosis-induced aggressionReview
      93. Haloperidol versus chlorpromazine for schizophreniaReview
      94. Haloperidol versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      95. Haloperidol versus placebo for schizophreniaReview
      96. Horticultural therapy for schizophreniaReview
      97. Hypnosis for schizophreniaReview
      98. Implementation of treatment guidelines for specialist mental health careReview
      99. Individual psychodynamic psychotherapy and psychoanalysis for schizophrenia and severe mental illnessReview
      100. Information and communication technology based prompting for treatment compliance for people with serious mental illnessReview
      101. Information and communication technology in patient education and support for people with schizophreniaReview
      102. Intensive case management for severe mental illnessReview
      103. Intercessory prayer for the alleviation of ill healthReview
      104. Intermittent drug techniques for schizophreniaReview
      105. Interventions to encourage uptake of cancer screening for people with severe mental illnessReview
      106. Interventions to reduce weight gain in schizophreniaReview
      107. Lamotrigine for schizophreniaReview
      108. Length of hospitalisation for people with severe mental illnessReview
      109. Levomepromazine for schizophreniaReview
      110. Life skills programmes for chronic mental illnessesReview
      111. Lithium for schizophreniaReview
      112. Loxapine for schizophreniaReview
      113. Maintenance treatment with antipsychotic drugs for schizophreniaReview
      114. Management of sexual dysfunction due to antipsychotic drug therapyReview
      115. Miscellaneous treatments for neuroleptic-induced tardive dyskinesiaReview
      116. Molindone for schizophrenia and severe mental illnessReview
      117. Monetary incentives for schizophreniaReview
      118. Morita therapy for schizophreniaReview
      119. Mother and baby units for schizophreniaReview
      120. Music therapy for people with schizophrenia and schizophrenia-like disordersReview
      121. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesiaReview
      122. New generation antipsychotics for first episode schizophreniaReview
      123. Newer atypical antipsychotic medication versus clozapine for schizophreniaReview
      124. Nicotine for schizophreniaReview
      125. Nidotherapy for people with schizophreniaReview
      126. Non-neuroleptic catecholaminergic drugs for neuroleptic-induced tardive dyskinesiaReview
      127. Olanzapine for schizophreniaReview
      128. Olanzapine IM or velotab for acutely disturbed/agitated people with suspected serious mental illnessesReview
      129. Olanzapine versus other atypical antipsychotics for schizophreniaReview
      130. Open general medical wards versus specialist psychiatric units for acute psychosesReview
      131. Oral health advice for people with serious mental illnessReview
      132. Oral paliperidone for schizophreniaReview
      133. Outcome measures and needs assessment tools for schizophrenia and related disordersReview
      134. Paliperidone palmitate for schizophreniaReview
      135. Penfluridol for schizophreniaReview
      136. Perazine for schizophreniaReview
      137. Pericyazine for schizophreniaReview
      138. Perphenazine for schizophreniaReview
      139. Pharmacological interventions for clozapine-induced hypersalivationReview
      140. Pharmacological treatments for psychosis-related polydipsiaReview
      141. Physical health care monitoring for people with serious mental illnessReview
      142. Pimozide for schizophrenia or related psychosesReview
      143. Polyunsaturated fatty acid supplementation for schizophreniaReview
      144. Preventive interventions for postnatal psychosisReview
      145. Problem solving skills for schizophreniaReview
      146. Prompts to encourage appointment attendance for people with serious mental illnessReview
      147. Psychoeducation for schizophreniaReview
      148. Psychosocial interventions for people with both severe mental illness and substance misuseReview
      149. Quetiapine for schizophreniaReview
      150. Quetiapine versus other atypical antipsychotics for schizophreniaReview
      151. Quetiapine versus typical antipsychotic medications for schizophreniaReview
      152. Risperidone dose for schizophreniaReview
      153. Risperidone versus olanzapine for schizophreniaReview
      154. Risperidone versus other atypical antipsychotic medication for schizophreniaReview
      155. Risperidone versus other atypical antipsychotics for schizophreniaReview
      156. Risperidone versus placebo for schizophreniaReview
      157. Risperidone versus typical antipsychotic medication for schizophreniaReview
      158. Seclusion and restraint for people with serious mental illnessesReview
      159. Sertindole for schizophreniaReview
      160. Sertindole versus other atypical antipsychotics for schizophreniaReview
      161. Sulpiride augmentation for schizophreniaReview
      162. Sulpiride for schizophreniaReview
      163. Sulpiride versus placebo for schizophreniaReview
      164. Supported employment for adults with severe mental illnessReview
      165. Supported housing for people with severe mental disordersReview
      166. Supportive therapy for schizophreniaReview
      167. Testosterone for schizophreniaReview
      168. Thioridazine for schizophreniaReview
      169. Token economy for schizophreniaReview
      170. Training to recognise the early signs of recurrence in schizophreniaReview
      171. Trifluoperazine for schizophreniaReview
      172. Trifluoperazine versus low-potency first-generation antipsychotic drugs for schizophreniaReview
      173. Trifluoperazine versus placebo for schizophreniaReview
      174. Twenty-four hour care for schizophreniaReview
      175. User-held personalised information for routine care of people with severe mental illnessReview
      176. Valproate for schizophreniaReview
      177. Vitamin E for neuroleptic-induced tardive dyskinesiaReview
      178. Vocational rehabilitation for people with severe mental illnessReview
      179. Ziprasidone for schizophrenia and severe mental illnessReview
      180. Ziprasidone versus other atypical antipsychotics for schizophreniaReview
      181. Zotepine for schizophreniaReview
      182. Zotepine versus other atypical antipsychotics for schizophreniaReview
      183. Zuclopenthixol acetate for acute schizophrenia and similar serious mental illnessesReview
      184. Zuclopenthixol decanoate for schizophrenia and other serious mental illnessesReview
      185. Zuclopenthixol dihydrochloride for schizophreniaReview
    3. Protocols
      1. Allopurinol and related drugs for schizophreniaProtocol
      2. Animal-assisted therapy for people with serious mental illnessProtocol
      3. Anticholinergics (various) for neuroleptic-induced parkinsonismProtocol
      4. Anticholinergics versus placebo for neuroleptic-induced parkinsonismProtocol
      5. Antiglucocorticoid and related treatments for psychosisProtocol
      6. Antioxidant treatments for schizophreniaProtocol
      7. Antipsychotic combinations for schizophreniaProtocol
      8. Antipsychotics for people with persistent negative symptoms of schizophreniaProtocol
      9. Aripiprazole dose for schizophreniaProtocol
      10. Aripiprazole for neuroleptic induced hyperprolactinaemiaProtocol
      11. Aripiprazole for people with schizophrenia whose illness has been partially responsive to clozapineProtocol
      12. Aripiprazole for psychosis-induced aggression or agitationProtocol
      13. Asenapine versus other atypical antipsychotics for schizophreniaProtocol
      14. Asenapine versus typical antipsychotics for schizophreniaProtocol
      15. Atomoxetine for schizophreniaProtocol
      16. Behavioural interventions for reducing weight gain in schizophreniaProtocol
      17. Celecoxib for schizophreniaProtocol
      18. Chlorpromazine versus atypical antipsychotic drugs for schizophreniaProtocol
      19. Clozapine dose for schizophreniaProtocol
      20. Cognitive behaviour therapy (group) for schizophreniaProtocol
      21. Cognitive behaviour therapy versus specific pharmacological treatments for schizophreniaProtocol
      22. Cognitive behaviour therapy versus standard care for schizophreniaProtocol
      23. Communication skills training for mental health professionals working with people with severe mental illnessProtocol
      24. De-escalation techniques for psychosis-induced aggression or agitationProtocol
      25. Dietary advice for schizophreniaProtocol
      26. Enhanced crisis planning for serious mental illnessProtocol
      27. First-rank symptoms for schizophreniaProtocolDiagnostic
      28. Fluphenazine (oral) versus atypical antipsychotics for schizophreniaProtocol
      29. Haloperidol for long-term aggression in psychosisProtocol
      30. Haloperidol versus first generation antipsychotics for schizophreniaProtocol
      31. HIV prevention advice for people with serious mental illnessProtocol
      32. Illness management and recovery programme for people with severe mental illnessProtocol
      33. Information and communication technology-based cognitive remediation for supporting treatment compliance for people with serious mental illnessProtocol
      34. Interventions for obsessive compulsive symptoms in people with schizophreniaProtocol
      35. Interventions for psychosis in adolescentsProtocol
      36. Interventions to reduce experiences of stigma and discrimination of people with mental illness and their caregiversProtocol
      37. Loxapine inhaler for psychosis-induced aggression or agitationProtocol
      38. Lurasidone versus placebo for schizophreniaProtocol
      39. Memantine for schizophreniaProtocol
      40. Modafinil for schizophreniaProtocol
      41. Mood stabilisers for schizoaffective disorderProtocol
      42. Olanzapine depot for schizophreniaProtocol
      43. Olanzapine discontinuation for schizophreniaProtocol
      44. Operational Criteria Checklist for Psychotic Illness and Affective Illness (OPCRIT+) for diagnosing schizophrenia in people with psychotic symptomsProtocolDiagnostic
      45. Peer support for schizophreniaProtocol
      46. Perphenazine versus low-potency first generation antipsychotic drugs for schizophreniaProtocol
      47. Pharmacological interventions for reducing weight gain in schizophreniaProtocol
      48. Pharmacological treatment for antipsychotic-related constipationProtocol
      49. Psychoeducation (brief) for people with serious mental illnessProtocol
      50. Psychoeducation for siblings of people with severe mental illnessProtocol
      51. Psychological interventions for psychosis in adolescentsProtocol
      52. Pyridoxal 5 phosphate for neuroleptic-induced tardive dyskinesiaProtocol
      53. Quetiapine for psychosis-induced aggression or agitationProtocol
      54. Quetiapine versus placebo for schizophreniaProtocol
      55. Rehabilitation programmes for schizophreniaProtocol
      56. Relapse prevention for schizophreniaProtocol
      57. Risperidone for psychosis induced aggression or agitationProtocol
      58. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuseProtocol
      59. Screening programmes for helping mental health professionals to detect violent victimisation in people with severe mental illnessProtocol
      60. Selective noradrenaline reuptake inhibitors for schizophreniaProtocol
      61. Smoking cessation advice for people with serious mental illnessProtocol
      62. Social skills programmes for schizophreniaProtocol
      63. Specialist interventions for homeless people with severe mental illnessProtocol
      64. Sulpiride dose for schizophreniaProtocol
      65. Sulpiride versus other antipsychotics for schizophreniaProtocol
      66. Transcranial magnetic stimulation for schizophreniaProtocol
      67. Transitional discharge techniques for people with serious mental illnessProtocol
      68. Treatments for delusional disorderProtocol
      69. Typical antipsychotics for psychosis in adolescentsProtocol
      70. Virtual reality for treatment compliance for people with serious mental illnessProtocol
      71. Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first-episode psychosisProtocolDiagnostic
      72. Yoga for schizophreniaProtocol
      73. Zotepine versus placebo for schizophreniaProtocol
      74. Zuclopenthixol versus placebo for schizophreniaProtocol
  48. Cochrane Sexually Transmitted Infections Group
  49. Cochrane Skin Group
  50. Cochrane Stroke Group
  51. Cochrane Tobacco Addiction Group
  52. Cochrane Upper Gastrointestinal and Pancreatic Diseases Group
  53. Cochrane Wounds Group

SEARCH